Tirzepatide is a GIP/GLP-1 receptor dual agonist that can simultaneously activate GLP-1 receptors and GIP receptor-mediated signaling pathways.

Tirzepatide is a GIP/GLP-1 receptor dual agonist that can simultaneously activate GLP-1 receptors and GIP receptor-mediated signaling pathways. GIP and GLP-1 are natural intestinal insulinotropic hormones that regulate blood sugar. Tirzepatide was approved by the US FDA (trade name: Mounjaro) in May 2022 for use in combination with diet control and exercise to improve the blood sugar control of adult type 2 diabetes patients. Last November, tirzepatide received FDA approval again (trade name: Zepbound) for the purpose of reducing weight and maintaining weight stability in obese or overweight adult patients. According to the press release, tirzepatide is the first approved GIP/GLP-1 receptor dual agonist.